Research

We apply a multidisciplinary approach to research that spans basic science, translational, health disparities, and outcomes, using what we learn to improve the lives of patients through new technologies, new care paradigms, and new understanding of the underpinnings of devastating diseases like esophageal and lung cancer.

Some examples of our impact in biomedical research:

Early Cancer Detection

With more than 25 years invested into research of esophageal and lung cancers, we’re able to investigate human disease not just through models but through the study of tissue samples.
Our tumor bank — one of the largest genetic databases of esophageal and lung cancers in the world — informs our insights into the mechanics of cancer progression so that we can ultimately develop better screening tools. We are collaborating with our Chemical Engineers to develop an early circulating tumor cell test for patients with early stage lung cancers.

We seek to be the first team to develop a powerful diagnostic test for esophageal cancer in the same way that routine colonoscopies offer the first chance to identify and even treat colon cancer at the earliest stages.

Healing Donor Lungs

We’re one of the first institutions in the country to use the technique of ex vivo lung perfusion (i.e. “incubator in a box”) to heal damaged or deconditioned donor lungs so they can be recovered for use as transplant organs.

Currently, fewer than 20% of possible donor lungs are healthy enough to transplant due to lung bruising that occurs at the time of death. With the “lung incubator” technique, we see potential to double the number of healthy donor lungs available to waiting patients.

We’re currently one of 13 centers nationwide participating in the trial to test this technology and approach.

Improving Esophageal Cancer Outcomes

Performing 100 to 150 esophagectomies each year, we’re among the highest-volume programs in the country with excellent outcomes, giving us the opportunity to set the standard of care and define what the best outcomes look like for patients with esophageal cancer. Current efforts include research to understand health disparities due to race, gender, and socioeconomic status. We are also evaluating new feeding paradigms to improve nutrition before and after esophagectomy. Other faculty are evaluating tumor response to chemoradiation, which occurs prior to operation. We are leaders in the state-wide and national databases on esophageal cancer outcomes that documents metrics for care and clinical quality as well.

Transforming Surgical Outcomes with Smarter Data

Using the wealth of data contained within CT scans, we’ve partnered with our surgical colleagues developing the new field of analytic morphomics, which uses computer algorithms and image analysis to develop predictive models of how patients will fare after an organ transplant or esophageal cancer treatment.

By compiling and analyzing the physical variations in our patient population, we’re able to identify patients who need “prehabilitation” to improve their health before their operation. The University of Michigan Department of Surgery is the creator and leader in this new science, which is changing the way surgeons think about patient outcomes.